GE HealthCare's Tax Rate Fell To 17.1% From 27.8%, Widening Its Earnings-Per-Share Gain

Third-quarter net income rose to $615 million while the adjusted per-share gain was smaller than the reported one.

Share
GE HealthCare's Tax Rate Fell To 17.1% From 27.8%, Widening Its Earnings-Per-Share Gain

GE HealthCare, which makes medical imaging equipment, patient monitors and diagnostic imaging agents, cut its third-quarter effective tax rate to 17.1% from 27.8% a year earlier, according to its 10-Q. That helped lift net income attributable to the company to $615 million from $446 million, and reported earnings per share outgrew the adjusted figure.

Reported and adjusted EPS diverge

Diluted earnings per share rose to $1.36 from $0.98. Adjusted EPS, which strips out tax items and other adjustments, rose to $1.34 from $1.07, so the standard-accounting gain outpaced the adjusted one, per the earnings release.

Pre-tax income was $752 million against $643 million. The provision for income taxes fell to $129 million from $179 million, a $50 million drop the company attributed mainly to foreign income tax reserve releases and changes in reconciling adjustments to recorded tax account balances, partly offset by a foreign tax audit settlement.

The adjusted reconciliation carries Spin-Off and other tax adjustments of negative $37 million this quarter, against positive $39 million a year ago. The adjusted effective tax rate was 22.0%, against 21.8%.

Operations also improved

Revenue rose 7.2% to $5.5 billion, or 6.2% organically. Operating income climbed to $805 million from $653 million, helped by volume, pricing and lower tariff expense. Direct tariffs cut operating income by $53 million in the quarter, against $95 million a year earlier.

The company also received $55 million of tariff refunds in the quarter after the Supreme Court ruled in February that the emergency-powers law did not authorize the tariffs. The company raised its full-year guidance.

Buybacks paused, SOFIE deal ahead

The company repurchased no shares in the third quarter. Over nine months it bought 4.7 million shares for about $300 million, and $500 million remains on its authorization.

It announced on October 5 an agreement to buy SOFIE Biosciences, a maker of PET radiopharmaceuticals on contract, for $945 million in cash. Closing is expected in the first half of 2027, subject to regulatory approvals.

In the 8-K, the company also said Jeannette Bankes will resign as head of Patient Care Solutions, with her last day November 15; Neal Sandy takes over November 16, per the release.

The SOFIE purchase is targeted to close in the first half of 2027.

Sources

More on GE HealthCare

All GE HealthCare (GEHC) coverage →